Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response

Antibody-drug conjugates (ADCs) have emerged as a revolutionary therapeutic class, combining the precise targeting ability of monoclonal antibodies with the potent cytotoxic effects of chemotherapeutics. Notably, ADCs have rapidly advanced in the field of breast cancer treatment. This innovative app...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Hannah L., Schwettmann, Blake, McArthur, Heather L., Chan, Isaac S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503805/
https://www.ncbi.nlm.nih.gov/pubmed/37712425
http://dx.doi.org/10.1172/JCI172156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503805/
https://www.ncbi.nlm.nih.gov/pubmed/37712425
http://dx.doi.org/10.1172/JCI172156

Ejemplares similares